Okey Stephanie 4

What Happened

• Stephanie Okey, a director of PTC Therapeutics (PTCT), exercised options to acquire 15,167 shares (14,000 + 1,167) at an exercise price of $33.63 per share (total exercise cost reported $510,066). She then sold those 15,167 shares in open-market transactions at $70.00 per share, generating proceeds of $1,061,690. The filing also records the corresponding derivative instruments as disposed (converted) in connection with the exercise.

Key Details

• Transaction date: March 10, 2026. Exercise price: $33.63; sale price: $70.00.
• Shares acquired via exercise: 15,167 (14,000 + 1,167). Shares sold: 15,167 (14,000 + 1,167). Sale proceeds: $1,061,690; reported acquisition cost: $510,066.
• Footnotes: F1 — trades were effected pursuant to a written Rule 10b5-1 plan adopted Nov 24, 2025. F2 — options were "currently exercisable."
• Shares owned after the transactions are not specified in the provided filing excerpt.
• Filing date: March 12, 2026 (the reported transactions occurred Mar 10); filing appears timely under standard Form 4 reporting windows.

Context

• This was an exercise of derivative awards (options) followed by same-day open-market sales — effectively a cashless exercise where exercised shares were immediately sold. The use of a pre-established 10b5-1 plan indicates the trades were made under a predetermined plan rather than ad hoc market timing.
• These entries do not by themselves indicate the insider’s view on company prospects; they document conversion of options and routine monetization.